These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9350394)

  • 1. Central sites of actions of zolmitriptan and sumatriptan: 5HT1B, 5HT1D and 5HT1F receptor distribution.
    Pascual J; Castro ME; Pazos A
    Cephalalgia; 1997 Oct; 17(6):711. PubMed ID: 9350394
    [No Abstract]   [Full Text] [Related]  

  • 2. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices.
    Stepień A; Chalimoniuk M; Strosznajder J
    Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
    Hoskin KL; Goadsby PJ
    Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat.
    Storer RJ; Goadsby PJ
    Brain; 1997 Dec; 120 ( Pt 12)():2171-7. PubMed ID: 9448572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat.
    Goadsby PJ; Knight YE
    Cephalalgia; 1997 May; 17(3):153-8. PubMed ID: 9170337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 5HT in migraine.
    Buzzi MG
    Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
    [No Abstract]   [Full Text] [Related]  

  • 7. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig).
    Proietti-Cecchini A; Afra J; Schoenen J
    Cephalalgia; 1997 Dec; 17(8):849-54; discussion 799. PubMed ID: 9453273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
    Whale R; Bhagwagar Z; Cowen PJ
    Psychopharmacology (Berl); 1999 Jul; 145(2):223-6. PubMed ID: 10463324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans.
    de Tommaso M; Guido M; Libro G; Sciruicchio V; Puca F
    Neurosci Lett; 2000 Jul; 289(1):57-60. PubMed ID: 10899408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain.
    Johnson DE; Rollema H; Schmidt AW; McHarg AD
    Eur J Pharmacol; 2001 Aug; 425(3):203-10. PubMed ID: 11513839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Zolmitriptan].
    Monseu G; Sternon J
    Rev Med Brux; 1998 Dec; 19(6):495-9. PubMed ID: 9916496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat.
    Pagniez F; Valentin JP; Vieu S; Colpaert FC; John GW
    Br J Pharmacol; 1998 Jan; 123(2):205-14. PubMed ID: 9489607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
    Martin GR
    Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
    Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
    Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.
    Ferrari MD
    Neurology; 1997 Mar; 48(3 Suppl 3):S21-4. PubMed ID: 9071266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the serotonin1B/1D receptor agonist zolmitriptan on motor cortical excitability in humans.
    Werhahn KJ; Förderreuther S; Straube A
    Neurology; 1998 Sep; 51(3):896-8. PubMed ID: 9748054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoradiographic distribution of [3H]sumatriptan-binding sites in post-mortem human brain.
    Pascual J; del Arco C; Romón T; del Olmo E; Castro E; Pazos A
    Cephalalgia; 1996 Aug; 16(5):317-22. PubMed ID: 8869766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
    MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
    Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Zolmitriptan].
    Le Jeunne C
    Presse Med; 1999 Sep; 28(28):1525-6. PubMed ID: 10526561
    [No Abstract]   [Full Text] [Related]  

  • 20. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.